

Planning Committee:

- **Harpreet S. Bajaj**, MD, MPH, ECNU, FACE
- **Christine Opsteen**, NP Adult, MN, CDE, CPT
- **Susie Jin**, RPh, CDE, CPT, BCGP
- **Henry Halapy**, RPh, CDE



Learning Objectives:

By completion of the program, the participant should be able to:

- Distinguish the difference between biosimilars and generic agents.
- Discuss the safety, efficacy, clinical role and opportunity of biosimilar insulins with patients and healthcare professionals.
- Recognize the pharmacokinetics, clinical considerations and applications of biosimilar insulins.
- Recommend, dispense, and prescribe biosimilar insulins (where applicable).



This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for **1.00 CEU**.


CCCEP File Number: **1066-2017-2134-I-P**.

This continuing education activity has been accredited by l'Ordre des Pharmaciens du Québec, which will grant **1 CEU** to pharmacists who have completed it successfully.

OPQ Activity Number: **1599**.

To learn more, visit

www.rxBriefCase.com/p-biosimilars-pharmacists-role.aspx



Case Study: Meet Trevor

Trevor is 60 years old, overweight and has type 2 diabetes. He is a financial advisor and insurance salesman. His stress levels fluctuate from day to day and he often misses lunch if he is travelling to see a client. He has been trying to lose weight through diet and exercise but results have been slow. He has been attempting to manage his T2D for 15 years, unfortunately his condition has progressed despite his efforts and his last A1C test was 9.2%. He has been prescribed insulin glargine (Lantus®) but is already asking about information about other alternatives like biosimilars after a discussion with his healthcare provider.

Watch Ask the Expert videos featuring Dr. Harpreet Singh Bajaj, MD, MPH, ECNU, FACE!

1. When would you use biosimilar insulin glargine rather than the reference insulin in clinical practice?
2. What is the best approach when switching to a biosimilar insulin from its reference insulin?
3. What is the same or what differs when counselling patients on biosimilars compared to the reference insulin?

Participate in the Discussion Forum!



1. What needs will biosimilars help fulfill for your patients who have diabetes?
2. How will biosimilars change your practice?
3. How likely are you to recommend a biosimilar? Why?
4. What concerns, if any, do have when it comes to a patient switching from insulin glargine to biosimilar insulin glargine?

For more information, visit
www.rxBriefCase.com/p-biosimilars-pharmacists-role.aspx